분자영상 및 방사화학

본문글자크기
  • [Pharmaceutics.] Preclinical Evaluation of hnRNPA2B1 Antibody in Human Triple-Negative Breast Cancer MDA-MB-231 Cells via PET Imaging

    경북대 / Abhinav Bhise, 박현, 유정수*

  • 출처
    Pharmaceutics.
  • 등재일
    2022 Aug 12
  • 저널이슈번호
    14(8):1677. doi: 10.3390/pharmaceutics14081677.
  • 내용

    바로가기  >

    Abstract
    Triple-negative breast cancer (TNBC) does not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Because TNBC lacks the expression of commonly targeted receptors, it is challenging to develop a new imaging agent for this cancer subtype. Heterogeneous nuclear ribonucleoproteins (hnRNPs) are RNA-protein complexes that have been linked to tumor development and progression. Considering the high expression of hnRNPA2B1, an hnRNP subtype, in TNBC MDA-MB-231 cells, this study aimed to develop a novel hnRNPA2B1 antibody-based nuclear imaging agent. The hnRNPA2B1-specific antibody was radiolabeled with 64Cu and evaluated in vitro and in vivo. The trans-cyclooctene (TCO) was functionalized on the antibody to obtain hnRNP-PEG4-TCO and reactive tetrazine (Tz) on the ultrastable bifunctional chelator PCB-TE2A-alkyne to yield PCB-TE2A-Tz for the inverse electron demand Diels-Alder reaction. The 64Cu-radiolabeled antibody was administered and imaged at 1-18 h time points for conventional imaging. Alternatively, the unlabeled antibody conjugate was administered, and 48 h later radiolabeled 64Cu-PCB-TE2A-Tz was administered to the same mice for the pretargeting strategy and imaged at the same time intervals for direct comparison. The tumor was successfully visualized in both strategies, and comparatively, pretargeting showed superior results. The 64Cu-PCB-TE2A-Tz was successfully clicked at the tumor site with hnRNP-PEG4-TCO and the non-clicked were concurrently eliminated. This led to increase the tumor uptake with extremely high tumor-to-background ratio manifested by positron emission tomography (PET) imaging and biodistribution studies.

     

     

    Affiliations

    Abhinav Bhise 1, Hyun Park 2, Woonghee Lee 1, Swarbhanu Sarkar 1, Yeong Su Ha 1, Subramani Rajkumar 1, Bora Nam 1, Jeong Eun Lim 1, Phuong Tu Huynh 1, Kiwoong Lee 1, Ji-Yoon Son 1, Jung Young Kim 2, Kyo Chul Lee 2, Jeongsoo Yoo 1
    1Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
    2Division of Applied RI, Korea Institute of Radiological and Medical Science, Seoul 01812, Korea.

  • 키워드
    hnRNPA2B1; immuno-PET; nuclear imaging; pretargeting; triple-negative breast cancer.
  • 편집위원

    Triple-negative breast cancer (TNBC)는 치료나 영상화를 위해 표적하기 위해 이용하는 일반적인 receptor 발현이 없기 때문에 연구에 어려움이 있다. 본 연구진은 Heterogeneous nuclear ribonucleoproteins (hnRNPs)의 subtype인 hnRNPA2B1이 발현되는 TNBC MDA-MB-231 세포를 표적으로 하는 hnRNPA2B1 항체에 Cu-64를 표지하여 종양동물 실험까지 진행한 TNBC 생체영상화 결과를 제시하고 있다.

    2022-11-01 16:03:07

  • 덧글달기
    덧글달기
       IP : 3.129.39.55

    등록